JUL 29, 2020 3:00 PM EDT

Advances and trends enabling the growth of immune-based cancer research and therapeutics

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Associate Vice President, Agilent Cell Analysis
    Biography



      David Ferrick began his career as a University of California professor, then entrepreneur and currently industry executive focused on life sciences tools, drug discovery and diagnostics specifically in the areas of immunology and cancer. He has commercialized many life science products into new and emerging markets based on nascent technologies and advanced several drug screening programs from target identification to preclinical testing. He has authored over 150 peer reviewed publications and 13 patents along with several book chapters. Dr. Ferrick received his Ph.D. in Microbiology and Immunology from Georgetown University in Washington D.C.


    Abstract

    With the recent successes of immunotherapies, a fresh breeze of optimism in the fight against cancer has reinvigorated the industry. Perhaps the greatest legacy will be the realization of the need to understand the interplay within the tumor microenvironment between tumor malignancy and protective immunity. Targeting the liabilities of tumors by ‘tuning’ cellular networks back into homeostatic harmony may just be the key to effective, durable therapies.

    Targeting and eliminating pathogenic cells is not good enough on its own to consistently achieve long-term survival. For example, immune cells that can eliminate tumors must persist in hostile, immunosuppressive microenvironments throughout tumor elimination and be capable of renewing protective surveillance. With the emergence of quantitative, live-cell analysis platforms researchers can make the necessary sensitive, time-resolved measurements to monitor the temporal components of an ever evolving cellular network.

    This talk will showcase new concepts and strategies to target cancer through an understanding of the immune response. We will discuss purpose-built applications that enable real-time measures of immune cell function, fate and fitness. This tool bench provides the capability to measure, engineer and control immune cell function, thus enabling translational researchers and developers to achieve the necessary level of therapeutic potency and safety

     

    Learning Objectives:

    1. Define new concepts and understanding of the interplay between tumors and immunity

    2. Identify new solutions to model and study tumor immunity over time

    3. Key strategies being tested to target tumor liabilities through immune-based drug design


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 30, 2021 8:00 AM PDT
    MAR 30, 2021 8:00 AM PDT
    DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
    Loading Comments...
    Show Resources